MetaCap

Enveric Biosciences (ENVB) vs GT Biopharma (GTBP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GT Biopharma is the larger company by market cap ($6.3 million vs $6.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENVB-9.70%GTBP-52.26%
+22%-17%-56%
Oct 7, 20261 yearNov 20, 2026
ENVB-6.90%GTBP-55.69%
+8%-25%-59%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENVB versus GTBP key metrics
MetricENVBGTBP
Share price$1.35$2.96
Market cap$6.04M$6.33M
1-day change-4.26%-6.92%
YTD return—+277.07%
1-year return—+303.27%
5-year return—-97.77%
EPS (TTM)$-13.01$-128.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-8.77M$-28.35M
52-week high$13.25$23.60
52-week low$1.17$2.87
Distance from 52-week high-89.81%-87.46%
Analyst consensus—none
Avg. price target upside—+2433.78%
Average volume56.55K78.16K
Shares outstanding4.48M2.14M
Employees51
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Enveric Biosciences

ENVB stock →

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About GT Biopharma

GTBP stock →

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

ENVB vs GTBP FAQ

Which is bigger, Enveric Biosciences or GT Biopharma?

GT Biopharma (GTBP) is larger, with a market capitalization of $6.33M compared with $6.04M for Enveric Biosciences (ENVB).

Are Enveric Biosciences and GT Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons